NYSEHealth CarePharmaceutical PreparationsPALO ALTO, CA

Evommune, Inc. EVMN

Ask your AI

Estimated market cap $315.50M41.35M shares, shares as of Nov 10, 2026CIK 2044725

Insider trades, 12 mo

3 buys · 9 sells

$2.28M sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q2 2026

105

83.8% of shares · 36 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Evommune, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 12, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Evommune, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

12 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Jul 8, 2026. Insiders have two business days to file.

Recent insider trades

Kyle Carver Chief Financial Officer	Jul 8 Form 4 ↗	Buy	+$13.3K 1,000 sh @ $13.26	-43.6%
Arthur S. Kirsch Director	Jul 7 Form 4 ↗	Buy	+$133.0K 10,000 sh @ $13.30	-43.7%
Jeegar Pravinkumar Patel Chief Scientific Officer	Jun 22 Form 4 ↗	Sale 10b5-1 plan	−$33.5K 1,488 sh @ $22.50	-67.5%
Drew Janice Suzann Chief of Dev. Operations	Jun 22 Form 4 ↗	Sale 10b5-1 plan	−$452.6K 20,000 sh @ $22.63	-67.5%
Luis C. Pena President & CEO, Director	Jun 22 Form 4 ↗	Sale 10b5-1 plan	−$168.9K 7,438 sh @ $22.71	-67.5%

All EVMN insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

34.64M shares

105 funds report EVMN. Values checked against market prices.

Funds own 95% of shares (Q2 2026)

105 funds hold the stock.

Q3 2026: 39% · 5,560 of ~8,900 funds reported so far

Q4 202586%
Q1 202697%
Q2 202695%
Q3 2026 (so far)39%

Reports for the quarter ending Sep 30, 2026 are still coming in (58 positions so far, against 120 the quarter before), so we compare the two complete quarters before it.

Q2 2026. 41 new, 36 added to, 13 trimmed, 20 exited since Q1 2026.

Top 13F holders
#
1	EQT Fund Management S.a r.l. 13F ↗	5.29M	$70.3M	+7.3%
2	RA Capital Management, L.P. 13F ↗	3.49M	$46.4M	unchanged
3	T. Rowe Price Associates Inc 13F ↗	1.94M	$25.8M	+73.4%
4	Pivotal bioVenture Partners Investment Advisor LLC 13F ↗	1.93M	$25.6M	unchanged
5	JPMorgan Chase & Co 13F ↗	1.55M	$23.4M	+6.4%
6	RTW Investments, LP 13F ↗	1.50M	$20.0M	unchanged
7	Nan Fung Group Holdings Ltd 13F ↗	1.44M	$19.2M	unchanged
8	Point72 Asset Management, L.P. 13F ↗	1.44M	$19.1M	+3823.4%
9	Andera Partners 13F ↗	1.39M	$18.5M	-26.6%
10	Eventide Asset Management, LLC 13F ↗	1.21M	$16.1M	unchanged

One of these funds reports its values in thousands of dollars; its figures are shown in dollars.

Download CSV Every fund that holds EVMN, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Evommune, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Evommune, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q4 2025	59	—	27.20M	$465.7M
Q1 2026	84	+25	34.77M	$797.8M
Q2 2026	105	+21	34.64M	$463.2M
Q3 2026	58	-47	16.30M	$134.7M

Each point is a quarter-end, from Q4 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (30054Y107). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q4 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes9 in 12 mo 8-K events7 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 6 in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active IPO history2 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Evommune, Inc.
Address: 1891 PAGE MILL RD, PALO ALTO, CA
Phone: (650) 223-7745
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company, emerging growth company
Incorporated in: DE
Listed as: EVMN (NYSE)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$7.63−$0.39 (−4.86%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $5.10 · High $8.62Nov 13, 2026

Aug 13, 2026Low $5.10 · High $15.01Nov 13, 2026

Nov 13, 2025Low $5.10 · High $31.57Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.